Bristol-Myers Squibb’s Opdivo and Yervoy has become the first approved immunotherapy combination option for a group of patients with advanced colorectal cancer.
Bristol-Myers Squibb’s cancer immunotherapy Opdivo is likely to gain another use in Europe after regulators recommended it after surgery for skin cancer.
Merck & Co’s blockbuster Keytruda has been approved in advanced second line cervical cancer, becoming the first drug in its class approved in the indication.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
